Stock data
Cartesian Therapeutics, Inc. (RNAC)
Cartesian Therapeutics, Inc. (RNAC) reported revenue of US$0.40M and net income of -US$130.30M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$0.40M | — | -US$143.41M | -US$130.30M | — |
| 2024 | US$38.27M | — | -US$43.90M | -US$77.42M | — |
| 2023 | US$26.00M | — | -US$86.42M | -US$219.71M | — |
| 2022 | US$110.78M | — | US$14.54M | US$35.38M | — |
| 2021 | US$85.08M | — | -US$4.60M | -US$25.69M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$0.00M | US$15.77M | — |
| 2026-03-31 | US$0.00M | -US$39.18M | — |
| 2025-12-31 | US$0.00M | -US$92.58M | — |
| 2025-09-30 | US$0.00M | -US$35.90M | — |
| 2025-06-30 | US$0.00M | US$15.89M | — |
| 2025-03-31 | US$0.40M | -US$17.71M | — |
| 2024-12-31 | -US$0.84M | -US$10.25M | — |
| 2024-09-30 | US$0.00M | -US$24.18M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.